References
- Agudelo D, Bourassa P, Bérubé G, Tajmir-Riahi HA. (2014). Intercalation of antitumor drug doxorubicin and its analogue by DNA duplex: structural features and biological implications. Int J Biol Macromol 66:144–50.
- Bhattarai N, Gunn J, Zhang M. (2010). Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev 62:83–99.
- Grant CS. (2015). Recurrence of papillary thyroid cancer after optimized surgery. Gland Surg 4:52–62.
- He M, Sui J, Chen Y. (2017). Localized multidrug co-delivery by injectable self-crosslinking hydrogel for synergistic combinational chemotherapy. J Mater Chem B 5:4852–62.
- Hu J, Hou Y, Park H, et al. (2012). Visible light crosslinkable chitosan hydrogels for tissue engineering. Acta Biomater 8:1730–8. (202).
- Hyun H, Park MH, Lim W, et al. (2018). Injectable visible light-cured glycol chitosan hydrogels with controlled release of anticancer drugs for local cancer therapy in vivo: a feasible study. Artif Cells Nanomed Biotechnol 1. DOI: 10.1080/21691401.2018.1470529.
- Ke W, Zhao Y, Huang R, et al. (2008). Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. J Pharm Sci 97:2208–16.
- Kuen C, Fakurazi S, Othman S, Masarudin M. (2017). Increased loading, efficacy and sustained release of silibinin, a poorly soluble drug using hydrophobically-modified chitosan nanoparticles for enhanced delivery of anticancer drug delivery systems. Nanomaterials (Basel) 7:379.
- Li S, Zhang D, Sheng S, Sun H. (2017). Targeting thyroid cancer with acid-triggered release of doxorubicin from silicon dioxide nanoparticles. Int J Nanomedicine 12:5993–6003.
- Matuszczyk A, Petersenn S, Bockisch A, et al. (2008). Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 40:210–13.
- Nguyen QT, Lee EJ, Huang MG, et al. (2015). Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits 8:30–40.
- Parhi R. (2017). Cross-linked hydrogel for pharmaceutical applications: a review. Adv Pharm Bull 7:515–30.
- Pommier Y, Leo E, Zhang H, Marchand C. (2010). DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17:421–33.
- Qi Y, Min H, Mujeeb A, et al. (2018). Injectable hexapeptide hydrogel for localized chemotherapy prevents breast cancer recurrence. ACS Appl Mater Interfaces 10:6972–81.
- Rocca JD, Liu D, Lin W. (2012). Are high drug loading nanoparticles the next step forward for chemotherapy? Nanomedicine (Lond) 7:303–5.
- De Souza R, Zahedi P, Allen CJ, Piquette-Miller M. (2010). Polymeric drug delivery systems for localized cancer chemotherapy. Drug Deliv 17:365–75.
- Sriamornsak P, Thirawong N, Weerapol Y, et al. (2007). Swelling and erosion of pectin matrix tablets and their impact on drug release behavior. Eur J Pharm Biopharm 67:211–19.
- Yang DH, Seo DI, Lee D-W, et al. (2017). Preparation and evaluation of visible light cured glycol chitosan hydrogel dressing containing dual growth factors for accelerated wound healing. J Ind Eng Chem 53:360–70.
- Yang F, Teves SS, Kemp CJ, Henikoff S. (2014). Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta 1845:84–9.
- Yoon S-J, Hyun H, Lee D-W, Yang DH. (2017). Visible light-cured glycol chitosan hydrogel containing a beta-cyclodextrin-curcumin inclusion complex improves wound healing in vivo. Molecules 22:1513.